• 1
    Sheiner PA, Magliocca JF, Bodian CA, Kim-Schluger L, Altaca G, Guarrera JV, et al. Long-term medical complications in patients surviving > or = 5 years after liver transplant. Transplantation 2000; 69:781789.
  • 2
    Jain A, Reyes J, Kashyap R, Dodson SF, Demetris AJ, Ruppert K, et al. Long-term survival after liver transplantation in 4,000 consecutive patients at a single center. Ann Surg 2000; 232:490500.
  • 3
    Fisher NC, Nightingale PG, Gunson BK, Lipkin GW, Neuberger JM. Chronic renal insufficiency following liver transplantation: A retrospective analysis. Transplantation 1998; 66:5966.
  • 4
    Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: Risk of development and treatment. Transplantation 2001; 72:19341939.
  • 5
    The US Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331:11101115.
  • 6
    Platz KP, Mueller AR, Blumhardt G, Bachmann S, Bechstein WO, Kahl A, et al. Nephrotoxicity following orthotopic liver transplantation. A comparison between cyclosporine and FK506. Transplantation 1994; 58:170178.
  • 7
    Gonwa TA. Hypertension and renal dysfunction in long-term liver transplant recipients. Liver Transpl 2001; 7(suppl 1):S22S26.
  • 8
    Groth CG, Backman L, Morales JM, Calne R, Kreis H, Lang P, et al. Sirolimus (sirolimus)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group. Transplantation 1999; 67:10361042.
  • 9
    Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, et al. Experience with the use of sirolimus in liver transplantation—Use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl 2000; 6:734740.
  • 10
    Kahan BD, Stepkowski SM, Napoli KL, Katz SM, Knight RJ, Van Buren C. The development of sirolimus: The University of Texas-Houston experience. Clin Transpl 2000: 145158.
  • 11
    Pescovitz MD, Govani M. Sirolimus and mycophenolate mofetil for calcineurin-free immunosuppression in renal transplant recipients. Am J Kidney Dis 2001; 38(suppl 2):S16S21.
  • 12
    Crawford DH, Endre ZH, Axelsen RA, Lynch SV, Balderson GA, Strong RW, et al. Universal occurrence of glomerular abnormalities in patients receiving liver transplants. Am J Kidney Dis 1992; 19:339344.